Free tool
FAERS Monitor: Vfend
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021630 or its brand name (Vfend, Voriconazole). Reports on generic versions are filed under their own applications.
Reports
30,722
Serious
28,342
92% of reports
Hospitalization
12,383
Death reported
8,951
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective4,336
- off label use2,510
- drug interaction2,408
- death1,481
- pyrexia1,455
- pneumonia1,359
- condition aggravated1,157
- bronchopulmonary aspergillosis1,066
- aspergillus infection943
- febrile neutropenia924
- respiratory failure865
- nausea796
- diarrhoea778
- product use in unapproved indication765
- dyspnoea758
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 315 |
| 2005 | 322 |
| 2006 | 418 |
| 2007 | 446 |
| 2008 | 429 |
| 2009 | 618 |
| 2010 | 855 |
| 2011 | 876 |
| 2012 | 1,097 |
| 2013 | 1,062 |
| 2014 | 1,063 |
| 2015 | 1,201 |
| 2016 | 1,422 |
| 2017 | 1,997 |
| 2018 | 2,244 |
| 2019 | 2,497 |
| 2020 | 2,370 |
| 2021 | 2,184 |
| 2022 | 2,258 |
| 2023 | 1,992 |
| 2024 | 1,898 |
| 2025 | 1,869 |
| 2026 | 1,288 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,023,437 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| aspergillus infectionSignal | 943 | 114.7 | 107.1 | 90,944 |
| bronchopulmonary aspergillosisSignal | 1,066 | 108.9 | 102.2 | 98,295 |
| drug interactionSignal | 2,408 | 10.5 | 10.1 | 20,615 |
| febrile neutropeniaSignal | 924 | 9.7 | 9.1 | 7,085 |
| respiratory failureSignal | 865 | 8.2 | 7.7 | 5,420 |
| pyrexiaSignal | 1,455 | 2.9 | 2.7 | 1,815 |
| pneumoniaSignal | 1,359 | 2.9 | 2.7 | 1,687 |
| condition aggravatedSignal | 1,157 | 2.6 | 2.5 | 1,161 |
| drug ineffectiveSignal | 4,336 | 2.3 | 2.2 | 3,225 |
| product use in unapproved indicationSignal | 765 | 2.1 | 2.0 | 453 |
| off label use | 2,510 | 2.0 | 1.9 | 1,237 |
| death | 1,481 | 1.2 | 1.1 | 41 |
| dyspnoea | 758 | 0.9 | 0.9 | 6 |
| diarrhoea | 778 | 0.8 | 0.8 | 30 |
| nausea | 796 | 0.7 | 0.6 | 116 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.